These three healthcare stocks could be outstanding additions to your portfolio.
News & Analysis: Johnson & Johnson
These quality businesses have lots of opportunities to keep raising what they give back to investors.
The case, which is premised on a unproven legal theory, could impact the course of future opioid litigation.
There's more good news with the fight against cancer than you might think.
And the analyst really likes one in particular.
These companies are not only prominent, but they're also putting a little more money directly into the hands of their stockholders.
Which of these top dividend-paying pharma stocks is the better buy right now?
Here's what management wants investors to know about the future of the company's pharmaceutical segment.
Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.
Predicting the future is never easy, but here's what might be in store for the healthcare giant.